Skip to main content

Rockwell Medical Value Stock - Dividend - Research Selection

Rockwell medical

ISIN: US7743741024 , WKN: 916118

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company\'s lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient\'s bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company\'s target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Rockwell Medical Appoints Joe Dawson to the Company's Board of Directors

2025-11-18
WIXOM, Mich., November 18, 2025--Joe Dawson is a seasoned executive who has extensive operational experience and a strong network in the renal care space.

Rockwell Medical, Inc. 2025 Q3 - Results - Earnings Call Presentation

2025-11-15
2025-11-15. The following slide deck was published by Rockwell Medical, Inc.

Rockwell Medical Inc (RMTI) Q3 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...

2025-11-12
Despite a significant drop in net sales, Rockwell Medical Inc (RMTI) shows resilience with improved adjusted EBITDA and strategic growth initiatives.

Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates

2025-11-12
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -25.00% and -5.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical: Q3 Earnings Snapshot

2025-11-12
RMTI) on Wednesday reported a loss of $1.8 million in its third quarter. The Wixom, Michigan-based company said it had a loss of 5 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $15.9 million in the period.

Rockwell Medical Announces Third Quarter 2025 Results

2025-11-12
WIXOM, Mich., November 12, 2025--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the third quarter 2025.

Rockwell Medical, Inc. (RMTI) Q3 2025 Earnings Call Transcript

2025-11-12
Rockwell Medical, Inc. (RMTI) Q3 2025 Earnings Call November 12, 2025 8:00 AM ESTCompany ParticipantsHeather Hunter - Senior VP & COOMark Strobeck -...

Rockwell Medical Names Rashad Brown Vice President, Manufacturing and Supply Chain

2025-11-11
WIXOM, Mich., November 11, 2025--Mr. Brown has built a distinguished career leading complex manufacturing and supply chain organizations.

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Misses Revenue Estimates

2025-11-06
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of -33.33% and -18.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical to Exhibit at ASN Kidney Week 2025

2025-10-28
WIXOM, Mich., October 28, 2025--Come visit Rockwell Medical in Booth #316 at ASN Kidney Week 2025 in Houston, TX.